Proven safety through 2 years in the GATHER trials²

Hi. I’m Dr. Esther Kim. I’m a vitreoretinal surgeon at Orange County Retina in California. And through it all, I’m a protector of my patients’ vision.

Right now, in GA, there isn’t the same urgency to intervene as we see with wet AMD. Instead of days or weeks, the treatment conversations can take months. In those months, patients could be losing precious vision. It’s important for the care team, including patients, to prioritize GA and initiate treatment sooner.

When we make the decision to try and preserve vision for longer, patients will naturally have questions and they should. They ask questions like “how will it feel?” and “is it safe?” It’s important for them to understand the consequences of GA and all their options for management and treatment. Having pragmatic, compassionate conversations with my patients helps them feel empowered to be part of their treatment decisions.

I talk to my patients about the efficacy and safety data for IZERVAY. Then I explain that there is treatment that may help preserve their vision for longer. I make sure that they have no infection or active swelling in or around their eye. I also discuss the risks associated with an eye injection such as an infection or retinal detachment. I reassure them that IZERVAY has no warning for intraocular inflammation or retinal vasculitis and that it has a low incidence of CNV. Many want to know more about the administration. I find when I use plain language, the patients are very understanding.

Accessibility is important to my patients. IZERVAY has an effective patient support program that many of my patients have found helpful. Prioritizing safety and accessibility, along with having robust conversations with my patients, gives me an extra level of confidence when treating with IZERVAY.

INDICATION

IZERVAY™ (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

IZERVAY is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation.

WARNINGS AND PRECAUTIONS

Endophthalmitis and Retinal Detachments

• Intravitreal injections, including those with IZERVAY, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.

Neovascular AMD

• In clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Over 24 months, the rate of neovascular (wet) AMD or choroidal neovascularization in the GATHER2 trial was 12% in the IZERVAY group and 9% in the sham group. Patients receiving IZERVAY should be monitored for signs of neovascular AMD.

Increase in Intraocular Pressure

• Transient increases in intraocular pressure (IOP) may occur after any intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed appropriately.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥5%) reported in patients receiving IZERVAY were conjunctival hemorrhage, increased IOP, blurred vision, and neovascular age-related macular degeneration.

Please see full Prescribing Information on IZERVAYecp.com.